Dabrafenib 75 MG Oral Capsule — RxCUI 1424918
RxNorm drug concept · Semantic clinical drug
RxCUI 1424918
Semantic clinical drug · SCD
● Current RxNorm concept 3 FDA products
3 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1424918
Official nameDabrafenib 75 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asdabrafenib (as dabrafenib methylsulfate 88.88 MG) 75 MG Oral Capsule
FDA products mapped3
Package NDCs mapped3
Reported Medicaid activity (SDUD)2,673 prescriptions · 24 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Dabrafenib: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Dabrafenib only works on tumors that carry a specific BRAF gene mutation — usually called V600E or V600K. Without that mutation, the drug won't help and could actually encourage tu...
- Why do I need a genetic test before starting dabrafenib?
- Yes, and this is one of the most important practical points. You need to take it on an empty stomach — at least 1 hour before eating or 2 hours after. A high-fat meal can cut by ro...
- Does it matter when I take dabrafenib relative to meals?
🕸️ Concept Web — How Dabrafenib 75 MG Oral Capsule Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Dabrafenib 75 MG Oral Capsule
RxCUI 1424918 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Dabrafenib
1424911IN
-
Dabrafenib
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Tafinlar
1425223BN
-
Tafinlar
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Dabrafenib Oral Capsule
1424915SCDF -
Dabrafenib Oral Product
1424913SCDG -
Dabrafenib Pill
1424914SCDG -
Dabrafenib Oral Capsule [Tafinlar]
1425225SBDF -
Tafinlar Oral Product
1425226SBDG -
Tafinlar Pill
1425227SBDG -
Oral Capsule
316965DF -
Oral Product
1151131DFG - +1 more in this family
-
Dabrafenib Oral Capsule
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Dabrafenib 75 MG
1424917SCDC -
Dabrafenib 75 MG Oral Capsule [Tafinlar]
1425230SBD -
Dabrafenib 75 MG [Tafinlar]
1425229SBDC
-
Dabrafenib 75 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Dabrafenib 75 MG
SCDC · 1424917 -
Dabrafenib Oral Capsule
SCDF · 1424915 -
Dabrafenib Oral Product
SCDG · 1424913 -
Dabrafenib Pill
SCDG · 1424914
Brand-Name Concepts
-
Dabrafenib 75 MG Oral Capsule [Tafinlar]
SBD · 1425230 -
Dabrafenib 75 MG [Tafinlar]
SBDC · 1425229 -
Dabrafenib Oral Capsule [Tafinlar]
SBDF · 1425225 -
Tafinlar Oral Product
SBDG · 1425226 -
Tafinlar Pill
SBDG · 1425227 -
Tafinlar
BN · 1425223
📦 FDA Products & Package NDCs
3 products · 3 package NDCs
3 package NDCs map to RxCUI 1424918 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00078-0681-66 | 120 CAPSULE in 1 BOTTLE (0078-0681-66) | Tafinlar | Novartis Pharmaceuticals Corporation | 2016-04-01 |
| 00078-0682-66 | 120 CAPSULE in 1 BOTTLE (0078-0682-66) | Tafinlar | Novartis Pharmaceuticals Corporation | 2016-04-12 |
| 00078-1154-21 | 210 TABLET, FOR SUSPENSION in 1 BOTTLE (0078-1154-21) | Tafinlar | Novartis Pharmaceuticals Corporation | 2023-03-16 |
Observed labelers:
Novartis Pharmaceuticals Corporation (3)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.